Login / Signup

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.

Jes Sanddal LindholtRikke SøgaardLars M RasmussenAnne MejldalJess LambrechtsenFlemming H SteffensenLars FrostKenneth EgstrupGrazina UrbonavicieneMartin BuskAxel Cosmus Pyndt Diederichsen
Published in: The New England journal of medicine (2022)
After more than 5 years, the invitation to undergo comprehensive cardiovascular screening did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age. (Funded by the Southern Region of Denmark and others; DANCAVAS ISRCTN Registry number, ISRCTN12157806.).
Keyphrases
  • risk factors
  • phase iii
  • randomized controlled trial
  • adipose tissue